Breast Cancer Clinical Trial

Clinical Utility of FES F18 PET/CT in Metastatic Breast Cancer Patients

Summary

This is a phase 4, multi-center, open-label, prospective cohort study to evaluate the clinical utility of Fluoroestradiol F18 (Cerianna) PET/CT to guide therapeutic management in ER-positive, HER2-negative metastatic breast cancer patients with progressive disease on first-line standard-of-care hormonal therapy. All patients will undergo a Cerianna PET/CT scan. The treating physician will complete a standardized questionnaire to indicate the second-line therapeutic management plan before the scheduled Cerianna PET/CT. After interpretation of Cerianna PET/CT by local radiologist or nuclear medicine physician, the treating physician will fill out a similar questionnaire to specify the final therapeutic decision. The proportion of patients with a change in therapeutic management plan based on Cerianna PET/CT results will be the primary endpoint. During the study follow-up period of 18 months, data on standard-of-care imaging, treatments/procedures received, and clinical outcomes will be collected. Patients will be asked to complete a health-related quality of life questionnaire at their screening, 6-month, and 18-month visit. Secondary endpoints include visual and quantitative heterogeneity assessment of tumor Cerianna uptake, and PFS rates at 6 months and 18 months after Cerianna PET/CT, which will be assessed between patients with and without a change in therapeutic management plan. Maximum duration of follow-up for each patient: 20 months. First patient first visit to last patient last visit: estimated 36 months.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Patient must sign informed consent prior to enrollment in this trial
The patient is a female ≥18 years old
Post-menopausal or pre-menopausal patient with known primary breast tumor(s) expressing ER in ≥1% of tumor cells by IHC
HER2-negative (0, 1+, 2+ fluorescence in situ hybridization (FISH) negative) primary lesion
MBC with at least 1 identifiable lesion on standard-of-care imaging assessment, outside of the liver, as confirmed by the investigator site
Patient with progressive disease on 1st line hormonal therapy (Aromatase Inhibitor) with or without a CDK4/6 inhibitor or mechanistic target of rapamycin (mTOR) inhibitor or phosphoinositide 3-kinases (PI3K) inhibitor
Patient must score at least 0, 1 or 2 on the Eastern Cooperative Oncology Group (ECOG) Performance Status
Life expectancy of at least 12 months
The patient must have undergone a standard-of-care imaging scan (according to National Comprehensive Cancer Network guidelines, e.g., CT and/or bone scan or fluorodeoxyglucose [FDG]-PET/CT) covering chest, abdomen, and pelvis no more than 45 days before screening

Exclusion Criteria:

Isolated hepatic metastases (taking into account the physiological hepatic high uptake of Cerianna)
Patient is on tamoxifen/toremifene treatment without 8-week washout, or on fulvestrant treatment without 28-week washout, (may block ER) before Cerianna PET/CT
Other evolutive malignant disease (non-melanoma skin cancer is allowed) or acute or chronic infectious disease (well-controlled infectious disease is allowed);
Patient has a history of >1 line of administered chemotherapy for metastatic disease ; prior chemotherapy in the adjuvant setting is allowed
Patient with a known allergy to any of the components of Cerianna
Woman of childbearing age who is not using effective contraception
Pregnant woman (per the Product Label and ensured using clinic's standard-of-care), or parturient or nursing mother
Patient presents with any other clinically active, serious, life-threatening disease, medical, or psychiatric condition, and/or who has a life expectancy of <12 months,or for whom study participation may compromise their management; and a patient who the investigator judges to be unsuitable in any reason
Inability to comply with any requirements of the protocol

Study is for people with:

Breast Cancer

Estimated Enrollment:

206

Study ID:

NCT05068726

Recruitment Status:

Recruiting

Sponsor:

Zionexa

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 4 Locations for this study

See Locations Near You

Long Beach Memorial Medical Center
Long Beach California, 90806, United States
Hoag Memorial Hospital Presbyterian
Newport Beach California, 92663, United States
Providence Saint John's Health Center
Santa Monica California, 90404, United States
Kettering Health Cancer Center
Kettering Ohio, 45429, United States

How clear is this clinincal trial information?

Study is for people with:

Breast Cancer

Estimated Enrollment:

206

Study ID:

NCT05068726

Recruitment Status:

Recruiting

Sponsor:


Zionexa

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.